Thermosensitive Hydrogel of Hydrophobically-modified Methylcellulose for Intravaginal Drug Delivery

Overview

Journal J Mater Sci Mater Med

Publisher Springer

Specialty Biomedical Engineering

Date 2012 May 10

PMID 22569735

Citations 8

Authors

Ning Li

Meihua Yu

Liandong Deng

Jun Yang

Anjie Dong

Affiliations

Soon will be listed here.

Abstract

Hydrogels with the advantages of prolonging drug release and administration convenience are necessary for intravaginal drug delivery to prevent sexual transmission of human immunodeficiency virus and other vaginal infections. In this study, the thermosensitive hydrogel of methylcellulose modified by stearic acid (MCS) were evaluated in the presence of NaCl and phosphates, which exhibited sol-to-gel transition performance at body temperature or even lower. The in vitro cytotoxicity and in vivo mucosal irritation were investigated and the results showed that MCS hydrogel possessed good biocompatibility similar with hydroxyethyl cellulose (HEC) gel. Significantly, the release studies revealed that MCS hydrogel could control tenofovir sustained release for 10 h without burst release, longer than that from HEC gel or poloxamer 407 hydrogel. Therefore, MCS thermosensitive hydrogel would be a promising carrier for intravaginal delivery of antiviral drugs for long time controlled release.

Citing Articles

Synthesis of Cyclodextrin-Based Multifunctional Biocompatible Hydrogels and Their Use in the Prevention of Intrauterine Adhesions (Asherman's Syndrome) after Surgical Injury.

Aksoy Erden B, Kurus M, Turkcuoglu I, Melekoglu R, Balcioglu S, Yigitcan B ACS Omega. 2024; 9(29):31957-31973.

PMID: 39072112 PMC: 11270706. DOI: 10.1021/acsomega.4c03655.

Cellulose-Based Hydrogels as Sustained Drug-Delivery Systems.

Ciolacu D, Nicu R, Ciolacu F Materials (Basel). 2020; 13(22).

PMID: 33233413 PMC: 7700533. DOI: 10.3390/ma13225270.

Nanotechnology-based antiviral therapeutics.

Chakravarty M, Vora A Drug Deliv Transl Res. 2020; 11(3):748-787.

PMID: 32748035 PMC: 7398286. DOI: 10.1007/s13346-020-00818-0.

A thermosensitive gel based on w1/o/w2 multiple microemulsions for the vaginal delivery of small nucleic acid.

Wang J, Wang Y, Wang Z, Wang F, He J, Yang X Drug Deliv. 2019; 26(1):168-178.

PMID: 30822166 PMC: 6407577. DOI: 10.1080/10717544.2019.1568622.

Nanoparticle Encapsulation for Antiretroviral Pre-Exposure Prophylaxis.

Khandalavala K, Mandal S, Pham R, Destache C, Shibata A J Nanotechnol Mater Sci. 2018; 4(2):53-61.

PMID: 29881781 PMC: 5987555. DOI: 10.15436/2377-1372.17.1583.

References

Bilensoy E, Rouf M, Vural I, Sen M, Hincal A . Mucoadhesive, thermosensitive, prolonged-release vaginal gel for clotrimazole:beta-cyclodextrin complex. AAPS PharmSciTech. 2006; 7(2):E38. PMC: 2750286. DOI: 10.1208/pt070238. View

Rohan L, Sassi A . Vaginal drug delivery systems for HIV prevention. AAPS J. 2009; 11(1):78-87. PMC: 2664883. DOI: 10.1208/s12248-009-9082-7. View

Buckheit Jr R, Watson K, Morrow K, Ham A . Development of topical microbicides to prevent the sexual transmission of HIV. Antiviral Res. 2009; 85(1):142-58. PMC: 2815091. DOI: 10.1016/j.antiviral.2009.10.013. View

Aranha C, Gupta S, Reddy K . Assessment of cervicovaginal cytokine levels following exposure to microbicide Nisin gel in rabbits. Cytokine. 2008; 43(1):63-70. DOI: 10.1016/j.cyto.2008.04.005. View

Zhou W, Zhao M, Zhao Y, Mou Y . A fibrin gel loaded with chitosan nanoparticles for local delivery of rhEGF: preparation and in vitro release studies. J Mater Sci Mater Med. 2011; 22(5):1221-30. DOI: 10.1007/s10856-011-4304-9. View

Liu J, Zhang S, Chen P, Cheng L, Zhou W, Tang W . Controlled release of insulin from PLGA nanoparticles embedded within PVA hydrogels. J Mater Sci Mater Med. 2007; 18(11):2205-10. DOI: 10.1007/s10856-007-3010-0. View

Ndesendo V, Pillay V, Choonara Y, Buchmann E, Bayever D, Meyer L . A review of current intravaginal drug delivery approaches employed for the prophylaxis of HIV/AIDS and prevention of sexually transmitted infections. AAPS PharmSciTech. 2008; 9(2):505-20. PMC: 2976928. DOI: 10.1208/s12249-008-9073-5. View

Bourinbaiar A, Root-Bernstein R, Abulafia-Lapid R, Rytik P, Kanev A, Jirathitikal V . Therapeutic AIDS vaccines. Curr Pharm Des. 2006; 12(16):2017-30. DOI: 10.2174/138161206777442119. View

Mayer K, Maslankowski L, Gai F, El-Sadr W, Justman J, Kwiecien A . Safety and tolerability of tenofovir vaginal gel in abstinent and sexually active HIV-infected and uninfected women. AIDS. 2006; 20(4):543-51. DOI: 10.1097/01.aids.0000210608.70762.c3. View

10.

Ji Q, Chen X, Zhao Q, Liu C, Cheng X, Wang L . Injectable thermosensitive hydrogel based on chitosan and quaternized chitosan and the biomedical properties. J Mater Sci Mater Med. 2009; 20(8):1603-10. DOI: 10.1007/s10856-009-3729-x. View

11.

Mahalingam A, Smith E, Fabian J, Damian F, Peters J, Clark M . Design of a semisolid vaginal microbicide gel by relating composition to properties and performance. Pharm Res. 2010; 27(11):2478-91. DOI: 10.1007/s11095-010-0244-1. View

12.

Krishnan S, Dunbar M, Minnis A, Medlin C, Gerdts C, Padian N . Poverty, gender inequities, and women's risk of human immunodeficiency virus/AIDS. Ann N Y Acad Sci. 2007; 1136:101-10. PMC: 2587136. DOI: 10.1196/annals.1425.013. View

13.

De Gaetano F, Ambrosio L, Raucci M, Marotta A, Catauro M . Sol-gel processing of drug delivery materials and release kinetics. J Mater Sci Mater Med. 2005; 16(3):261-5. DOI: 10.1007/s10856-005-6688-x. View

14.

Cutler B, Justman J . Vaginal microbicides and the prevention of HIV transmission. Lancet Infect Dis. 2008; 8(11):685-97. PMC: 2627483. DOI: 10.1016/S1473-3099(08)70254-8. View

15.

Schwartz J, Ballagh S, Kwok C, Mauck C, Weiner D, Rencher W . Fourteen-day safety and acceptability study of the universal placebo gel. Contraception. 2007; 75(2):136-41. DOI: 10.1016/j.contraception.2006.09.003. View

16.

Das Neves J, Bahia M . Gels as vaginal drug delivery systems. Int J Pharm. 2006; 318(1-2):1-14. DOI: 10.1016/j.ijpharm.2006.03.012. View

17.

Kang Y, Kim G, Kim J, Kim D, Lee B, Yoon S . In vivo efficacy of an intratumorally injected in situ-forming doxorubicin/poly(ethylene glycol)-b-polycaprolactone diblock copolymer. Biomaterials. 2011; 32(20):4556-64. DOI: 10.1016/j.biomaterials.2011.03.007. View

18.

Tien D, Schnaare R, Kang F, Cohl G, McCormick T, Moench T . In vitro and in vivo characterization of a potential universal placebo designed for use in vaginal microbicide clinical trials. AIDS Res Hum Retroviruses. 2005; 21(10):845-53. DOI: 10.1089/aid.2005.21.845. View

19.

Vermani , Garg . The scope and potential of vaginal drug delivery. Pharm Sci Technol Today. 2000; 3(10):359-364. DOI: 10.1016/s1461-5347(00)00296-0. View

20.

Brown T, Tyring S . An overview of sexually transmitted diseases. Part I. J Am Acad Dermatol. 1999; 41(4):511-32. View